Eur J Ophthalmol 2009; 19: 870 - 872Short-term topical bevacizumab (Avastin) therapy may potentially offer a safer and more effective alternative in treating graft rejection after penetrating keratoplasty (corneal transplant).
Eur J Ophthalmol 2009; 19: 870 - 872
No comments:
Post a Comment
Leave a Comment or Question: